Vicarious Surgical (RBOTW) Research & Development (2020 - 2025)

Vicarious Surgical (RBOTW) has 6 years of Research & Development data on file, last reported at $8.0 million in Q3 2025.

• Research & Development for Q3 2025 came in at $8.0 million, down 25.99% year-over-year; the trailing twelve-month figure through Sep 2025 was $34.9 million (down 13.05% YoY), and the FY2024 annual result was $40.2 million, down 15.6% from the prior year.
• Research & Development fell to $8.0 million in Q3 2025 per RBOTW's latest filing, from $9.0 million in the prior quarter.
• Over five years, Research & Development peaked at $13.4 million in Q1 2023 and troughed at $3.6 million in Q1 2021.
• A 5-year average of $9.5 million and a median of $9.8 million in 2022 frame the typical range for Research & Development.
• The sharpest annual moves came in 2021 and 2023: Research & Development surged 212.14% in 2021, then slipped 28.7% in 2023.
• A 5-year view of Research & Development shows it stood at $9.3 million in 2021, then climbed by 28.33% to $11.9 million in 2022, then declined by 28.7% to $8.5 million in 2023, then slipped by 0.06% to $8.5 million in 2024, then fell by 5.55% to $8.0 million in 2025.
• Business Quant data shows RBOTW's Research & Development at $8.0 million in Q3 2025, $9.0 million in Q2 2025, and $9.4 million in Q1 2025.